Patents by Inventor Pascal Birman

Pascal Birman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF PRIMARY BILIARY CHOLANGITIS
    Publication number: 20260240799
    Abstract: The present invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of elafibranor, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-propyl]phenoxy]-2-methylpropanoic acid (GFT1007), and a pharmaceutically acceptable salt of elafibranor or GFT1007, for use in a method for reducing fatigue in subject having primary biliary cholangitis (PBC). The pharmaceutical composition of the invention provides a significative reduction of the PROMIS Fatigue T-score (PROMIS Short Form—Fatigue 7a questionnaire (V1.0)) from baseline in a subject having PBC.
    Type: Application
    Filed: April 10, 2026
    Publication date: August 20, 2026
    Inventors: Pascal Birman, Julie Dietrich
  • ELAFIBRANOR FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS
    Publication number: 20260240800
    Abstract: The present invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of elafibranor, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-propyl]phenoxy]-2-methylpropanoic acid (GFT1007), and a pharmaceutically acceptable salt of elafibranor or GFT1007, for use in a method for treating primary biliary cholangitis (PBC) in a subject having PBC with a baseline plasma alkaline phosphatase (ALP) level of more than 1.67×ULN and at most 3×ULN.
    Type: Application
    Filed: April 14, 2026
    Publication date: August 20, 2026
    Inventors: Pascal Birman, Alice Roudot, David Magrez
  • Compositions and methods for the treatment of primary biliary cholangitis
    Patent number: 12589086
    Abstract: The invention relates to a pharmaceutical composition comprising elafibranor or a pharmaceutically acceptable salt thereof, for use to treat primary biliary cholangitis (PBC) in a subject intolerant to ursodeoxycholic acid (UDCA).
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: March 31, 2026
    Assignee: Genfit
    Inventors: Pascal Birman, Alice Roudot, David Magrez, Benoit Noel
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS
    Publication number: 20230301951
    Abstract: The invention relates to a pharmaceutical composition comprising elafibranor or a pharmaceutically acceptable salt thereof, for use to treat primary biliary cholangitis (PBC) in a subject intolerant to ursodeoxycholic acid (UDCA).
    Type: Application
    Filed: August 25, 2021
    Publication date: September 28, 2023
    Inventors: Pascal Birman, Alice Roudot, David Magrez, Benoit Noel
  • TREATMENT OF PRIMARY BILIARY CHOLANGITIS WITH ELAFIBRANOR
    Publication number: 20230052189
    Abstract: The invention relates to a pharmaceutical composition comprising elafibranor, GFT1007 or a pharmaceutically acceptable salt of elafibranor or of GFT1007, for use to treat primary biliary cholangitis (PBC) without provoking and/or worsening at least one adverse event associated to PBC.
    Type: Application
    Filed: February 4, 2021
    Publication date: February 16, 2023
    Inventors: Stephanie Petit, Julie Mouton, Julie Dietrich, Omar Olhaye, Pascal Birman